References
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
- Weber C, Badimon L, Mach F, et al. Therapeutic strategies for atherosclerosis and atherothrombosis: past, present and future. Thromb Haemost. Forthcoming 2017.
- Kannel WB, Dawber TR, Friedman GD, et al. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann Intern Med. 1964;61:888–899.
- Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85(4):1234–1241.
- Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353(6341):265–267.
- Keene D, Price C, Shun-Shin MJ, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. Bmj. 2014;349:g4379.
- Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572–580.
- Bursill CA, Castro ML, Beattie DT, et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2010;30(9):1773–1778.
- Van Der Vorst EP, Vanags LZ, Dunn LL, et al. High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. Faseb J. 2013;27(4):1413–1425.
- Suzuki M, Pritchard DK, Becker L, et al. High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation. 2010;122(19):1919–1927.
- De Nardo D, Labzin LI, Kono H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2014;15(2):152–160.
- Van Der Vorst EP, Theodorou K, Wu Y, et al. High-density lipoproteins exert pro-inflammatory effects on macrophages via passive cholesterol depletion and PKC-NF-kappaB/STAT1-IRF1 signaling. Cell Metab. 2017;25(1):197–207.
- Smoak KA, Aloor JJ, Madenspacher J, et al. Myeloid differentiation primary response protein 88 couples reverse cholesterol transport to inflammation. Cell Metab. 2010;11(6):493–502.
- Sanson M, Distel E, Fisher EA. HDL induces the expression of the M2 macrophage markers arginase 1 and Fizz-1 in a STAT6-dependent process. PLoS One. 2013;8(8):e74676.
- Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res. 2014;55(2):168–179.